The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: A national cohort (Comunica-TTD working group).
 
FEDERICO LONGO
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; MSD; Roche; SERVIER
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Ferrer; Lilly; Merck; MSD; Roche; Sanofi; SERVIER
 
Oscar Alfredo Castillo Trujillo
No Relationships to Disclose
 
Juan José Serrano Domingo
No Relationships to Disclose
 
Roberto Martin Huertas
No Relationships to Disclose
 
Elena Corral de la Fuente
No Relationships to Disclose
 
Alberto San Juan del Moral
No Relationships to Disclose
 
Jaime Portela
No Relationships to Disclose
 
Juana Maria Cano
No Relationships to Disclose
 
Pablo Reguera Puertas
No Relationships to Disclose
 
Mercedes Rodríguez Garrote
No Relationships to Disclose
 
Marta Izquierdo Manuel
No Relationships to Disclose
 
Paula Jiménez-Fonseca
Other Relationship - IPSEN
 
Alfredo Carrato
Consulting or Advisory Role - Bayer; Celgene; Merck; MSD Oncology; Roche; Servier; Shire
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Merck
 
Enrique Aranda
No Relationships to Disclose